Effects of high dose raloxifene in selected patients with advanced breast carcinoma

Cancer

Volumn 88, Issue 9, 2000, Pages 2047-2053

  Gradishar, William ^a   Glusman, Joan ^b   Lu, Yili ^b   Vogel, Charles ^c   Cohen, Fredric J ^b   Sledge Jr , George W ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Comprehensive Cancer Research Group ^*  (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

Antiestrogen; Breast carcinoma; Endocrine treatment; Postmenopausal women; Raloxifene; Selective estrogen receptor modulator (SERM)

Indexed keywords

ANTIESTROGEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER RISK; CLINICAL ARTICLE; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HORMONAL THERAPY; HUMAN; INSOMNIA; LIPID METABOLISM; NAUSEA; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; TUMOR VOLUME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CONFIDENCE INTERVALS; DISEASE PROGRESSION; ESTROGEN ANTAGONISTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTMENOPAUSE; QUALITY OF LIFE; RALOXIFENE; RECEPTORS, ESTROGEN; REMISSION INDUCTION; SAFETY; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SURVIVAL RATE; TAMOXIFEN;

EID: 0034193122     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2047::AID-CNCR10>3.0.CO;2-E     Document Type: Article

References (29)

1. Jaiyesimi LA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
2. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
3. Love RR, Wiebe DA, Newcomb PA, Cameron L, Leventhal H, Jordan VC, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 1991; 115:860-4.
4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
5. Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans? J Clin Oncol 1998;16:779-92.
6. Mitlak BH, Cohen FJ. In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. Horm Res 1997;48:155-63.
7. Cohen FJ, Watts S, Shah A, Akers R, Plouffe L. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60. Obstet Gynecol 2000;95:104-10.
8. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337: 1641-7.
9. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-9.
10. Boss SM, Huster WJ, Neild JA, Giant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64.
11. Clemens JA, Bennett DR, Black LJ, Jones CD. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983;32:2869-75.
12. Wakeling AE, Valcaccia B, Newboult E, Green LR. Nonsteroidal antioestrogens - receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984;20:111-20.
13. Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst 1996;88:123-5.
14. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of LY156758 in metastatic breast cancer. Oncology 1988;45:344-5.
15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-88.
16. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999;281:2189-97.
17. American Joint Committee on Cancer. Manual for the staging of cancer. In: Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. 4th ed. Philadelphia: JB Lippincott Company, 1992.
18. World Heath Organization. The WHO handbook for reporting results of cancer treatment. Publication No. 48. Geneva, Switzerland: The World Health Organization, 1979.
19. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996;11:835-42.
20. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
21. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997;15:974-86.
22. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol 1996;23:494-505.
23. Robertson JF, Willsher P, Cheung KL, Blarney RW. The clinical relevance of static disease (no change) category for 6 mo on endocrine therapy in patients with breast cancer [meeting abstract]. Proc Annu Meet Am Soc Clin Oncol 1996;15: A69.
24. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmen J. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group. Breast Cancer Res Treat 1997;45:251-62.
25. Kuss JT, Muss HB, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. Breast Cancer Res Treat. 1997;42:265-74.
26. Pyrhonen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, et al. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study. Br J Cancer 1997;76:270-7.
27. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 1994;343:1318-21.
28. Brodie AM, Njar VC. Aromatase inhibitors and breast cancer. Semin Oncol 1996;23(4 Suppl 9):10-20.
29. England GM, Jordan VC. Pure antiestrogens as a new therapy for breast cancer. Oncol Res 1997;9:397-402.